AREL1: A Potential Drug Target for Apoptosis-Resistant HECT-Type E3 Ubiquitin Transferase 1

Target Name: AREL1

NCBI ID: G9870

AREL1

AREL1: A Potential Drug Target for Apoptosis-Resistant HECT-Type E3 Ubiquitin Transferase 1

Apoptosis, the process of programmed cell death, is a natural response to tissue damage, infection, or uncontrolled growth. It is a critical cell signaling mechanism that helps maintain tissue homeostasis and eliminate damaged or dysfunctional cells. However, uncontrolled apoptosis can lead to diseases such as cancer, neurodegenerative disorders, and cardiovascular diseases. Therefore, the discovery of potential drug targets and biomarkers for apoptosis-resistance is of great interest.

AREL1, a HECT-type E3 ubiquitin transferase 1, has been identified as a potential drug target for apoptosis-resistance. HECT-type E3 ubiquitin transferases (HETs) are a family of enzymes that play a crucial role in the regulation of DNA double-strand break repair, apoptosis, and other cellular processes. E3 ubiquitin transferases are known to have a critical role in the formation of protein ubiquitinylated targets, which can modulate protein stability, localization, and activity.

AREL1, a HECT-type E3 ubiquitin transferase 1, was identified as a potential drug target for apoptosis-resistance due to its unique properties. It has been shown to have a high degree of apoptosis-resistance, as it is able to induce apoptosis in cell culture models, but not in living organisms. Additionally, Arel1 has been shown to have a unique mechanism of inhibition, as inhibition of Arel1 has been shown to increase the level of pro-apoptotic activity in cell culture models.

The potential drug target for Arel1 is the inhibition of its activity, which can be achieved by inhibiting the activity of Arel1's inhibitors or by inhibiting the formation of ubiquitinylated targets. There are several potential strategies for achieving this goal, including inhibition of the kinase activity of Arel1, inhibition of the ubiquitinylation process, or inhibition of the DNA double-strand break repair process.

In addition to its potential as a drug target, Arel1 is also a potential biomarker for apoptosis-resistance. The ability of Arel1 to induce apoptosis in cell culture models makes it an attractive tool for the study of apoptosis-resistance. Additionally, the unique mechanism of inhibition of Arel1 has been shown to be specific to this protein, making it a valuable tool for the study of apoptosis-resistance mechanisms.

Conclusion

In conclusion, Arel1, a HECT-type E3 ubiquitin transferase 1, has been identified as a potential drug target for apoptosis-resistance due to its unique properties. Its ability to induce apoptosis in cell culture models makes it an attractive tool for the study of apoptosis-resistance mechanisms. Additionally, the unique mechanism of inhibition of Arel1 has been shown to be specific to this protein, making it a valuable tool for the study of apoptosis-resistance mechanisms. Further research is needed to fully understand the potential of Arel1 as a drug target and biomarker for apoptosis-resistance.

Protein Name: Apoptosis Resistant E3 Ubiquitin Protein Ligase 1

Functions: E3 ubiquitin-protein ligase that catalyzes 'Lys-11'- or 'Lys-33'-linked polyubiquitin chains, with some preference for 'Lys-33' linkages (PubMed:25752577). E3 ubiquitin-protein ligases accept ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates (PubMed:23479728, PubMed:31578312). Ubiquitinates SEPTIN4, DIABLO/SMAC and HTRA2 in vitro (PubMed:23479728). Modulates pulmonary inflammation by targeting SOCS2 for ubiquitination and subsequent degradation by the proteasome (PubMed:31578312)

The "AREL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AREL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets